You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic & clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?

You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic & clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?

CLICK HERE FOR CME CREDIT

You have introduced the concept of “progressive atherosclerotic burden” to characterize the multiplicity of biologic, metabolic, and clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Michael H. Davidson, MD, FACC, FACP, FNLA

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Clinical Professor
Director of Preventive Cardiology
The University of Chicago Hospitals and Clinic
Pritzker School of Medicine
Chicago, Illinois